MONSEY, N.Y., Aug. 19, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP has renewed its investigation into the fairness of the proposed sale of Silk Road Medical, Inc. (Nasdaq: SILK) (“SILK”) to Boston Scientific Corporation for $27.50 per share in cash.
On July 29, 2024, SILK filed a definitive proxy concerning the proposed sale with the SEC.
Based on our review of the proxy, we have renewed our investigation into whether there are any undisclosed potential conflicts of interest.
If you remain a SILK shareholder and question the fairness of the price or have any other concerns, you may contact our firm at the following link to discuss your legal rights at no charge:
https://wohlfruchter.com/cases/silk-road-medical/
Alternatively, you may contact us by phone at 866-833-6245, or via email at alerts@wohlfruchter.com.
About Wohl & Fruchter
Wohl & Fruchter LLP has for over a decade been representing investors in litigation arising from fraud and other corporate misconduct, and recovered hundreds of millions of dollars in damages for investors. Please visit our website, www.wohlfruchter.com, to learn more about our Firm, or contact one of our partners.
Contact:
Wohl & Fruchter LLP
Joshua E. Fruchter
Toll Free 866.833.6245
alerts@wohlfruchter.com
www.wohlfruchter.com
